![]() | ![]() |
Formats:
|
||||||||||
Copyright © 2006, Cold Spring Harbor Laboratory Press Quantitative microarray profiling provides evidence against widespread coupling of alternative splicing with nonsense-mediated mRNA decay to control gene expression 1Banting and Best Department of Medical Research, 2Department of Molecular and Medical Genetics, 3Department of Electrical and Computer Engineering, 4Program in Proteomics and Bioinformatics, University of Toronto, Ontario, M5G 1L6, Canada; 5Department of Biochemistry and Biophysics, School of Medicine and Dentistry, University of Rochester, Rochester, New York 14642, USA 6These authors contributed equally to this work. 7Corresponding author.E-MAIL b.blencowe/at/utoronto.ca; FAX (416) 978-8528. Received October 11, 2005; Accepted November 23, 2005. This article has been cited by other articles in PMC.Abstract Sequence-based analyses have predicted that ~35% of mammalian alternative splicing (AS) events produce premature termination codon (PTC)-containing splice variants that are targeted by the process of nonsense-mediated mRNA decay (NMD). This led to speculation that AS may often regulate gene expression by activating NMD. Using AS microarrays, we show that PTC-containing splice variants are generally produced at uniformly low levels across diverse mammalian cells and tissues, independently of the action of NMD. Our results suggest that most PTC-introducing AS events are not under positive selection pressure and therefore may not contribute important functional roles. Keywords: Alternative splicing, microarray analysis, nonsense-mediated mRNA decay, premature termination codon Alternative splicing (AS), the process by which exons in transcripts are joined in different combinations to generate multiple mRNA variants, represents an important mechanism for the expression of structurally and functionally distinct proteins from a limited number of genes (Graveley 2001; Black 2003). Regulation of AS plays critical roles in cell growth, differentiation, and cell death, and aberrant AS has been implicated in many human diseases (Smith and Valcarcel 2000; Caceres and Kornblihtt 2002; Cartegni et al. 2002). It has been estimated that at least 74% of human genes contain one or more alternative exons (Johnson et al. 2003), yet it is not known to what extent the resulting splice variants specify functionally relevant transcripts and proteins. Previous studies have shown that the introduction of premature termination codons (PTCs) in spliced transcripts can activate transcript degradation via the process of nonsense-mediated mRNA decay (NMD) (Hillman et al. 2004; Maquat 2004; Alonso 2005). NMD is important for the removal of nonfunctional PTC-containing transcripts (Mendell et al. 2004; Mitrovich and Anderson 2005). It has also been shown to function in the autoregulation of transcript levels of several RNA-binding proteins, including splicing factors (Morrison et al. 1997; Sureau et al. 2001; Wollerton et al. 2004; for review, see Lareau et al. 2004). In addition to a PTC, NMD requires a set of upstream frameshift (UPF) protein factors that associate with the spliced transcripts via interactions with a post-splicing exon junction complex (Lykke-Andersen et al. 2000; Kim et al. 2001; Lejeune et al. 2002; Gehring et al. 2003). One or more of the UPF proteins, including the essential UPF1 protein (Medghalchi et al. 2001), subsequently recruit RNA nucleases that initiate degradation of the PTC-containing transcripts (Lejeune et al. 2003; for review, see Baker and Parker 2004). Recent bioinformatics analyses of expressed sequence tag (EST) and cDNA sequence data have predicted that ~35% of AS events have the potential to introduce PTCs that could elicit NMD of transcripts (Green et al. 2003; Lewis et al. 2003). This finding led to speculation that NMD activated by AS may represent a widely used mechanism by which gene expression is down-regulated (Hillman et al. 2004; Neu-Yilik et al. 2004; Alonso 2005; Lejeune and Maquat 2005), and it has also been proposed that the introduction of PTCs by AS serves as a mechanism for the tissue-specific regulation of gene expression (Hillman et al. 2004; Holbrook et al. 2004; Raes and Van de Peer 2005). However, no study has yet examined experimentally the actual levels of PTC-containing mRNA splice variants in normal cells and tissues, and it is not known to what extent AS functions globally to regulate transcript levels via NMD. Moreover, although it has been reported that short interfering duplex RNA (siRNA)-mediated depletion of UPF1 in cultured cells results in changes in the levels (both up and down) of transcripts for ~9% of genes (Mendell et al. 2004), it was not determined to what extent these effects might be coupled to AS events that introduce PTCs. In the present study, we used a recently described quantitative microarray platform (Pan et al. 2004) to determine the relative levels of PTC-containing versus non-PTC-containing splice variants in mammalian cells and tissues of diverse origin. The majority of PTC-containing splice variants were found to be present at low steady-state abundance and only very rarely appeared to be subject to tissue-specific regulation. Efficient depletion of UPF1 resulted in increased levels of PTC-containing splice variants for some genes, but only a small proportion of the total number of genes that encode PTC-introducing AS events displayed pronounced UPF1-dependent changes in alternative splicing levels, and these effects were not significantly correlated with the effects of UPF1 depletion on transcripts levels. These experimental data, together with supporting computational analyses, suggest that approximately one-third or more of AS events located within the open reading frames (ORFs) of mammalian genes produce PTC-containing splice variant mRNAs that are not under significant selection pressure, and therefore may not play important functional roles. Results and Discussion Quantitative profiling of PTC-containing splice variants in normal mammalian tissues A recently described quantitative AS microarray platform (Pan et al. 2004) was employed to survey the levels of splice variants produced from genes that do or do not encode PTC-introducing AS events. This survey was initially conducted across 10 diverse adult mouse tissues. The AS microarray contains sets of six oligonucleotide probes (specific for exon and splice junction sequences) to monitor the inclusion/exclusion levels of 3126 sequence-verified cassette-type alternative exons. A computer algorithm, referred to as the “Generative model for the Alternative Splicing Array Platform” (GenASAP), was used to infer the percent exclusion levels of each alternatively spliced exon (i.e., the percentage of the total transcripts from a gene with a skipped alternative exon) (Pan et al. 2004). GenASAP also generates a confidence rank for each percent exclusion value. Percent exclusion levels in the top half of the ranks correlate well with independent RT-PCR measurements and were used for most of the analyses in the present study (refer to Supplementary Tables S1-S3 for data). Using this system, we compared the percent exclusion levels of alternative exons represented on the microarray that have the potential to introduce PTCs that can activate NMD, with the percent exclusion levels of alternative exons that do not have the potential to introduce PTCs that can activate NMD (Fig. 1A
Analysis of transcript sequence data corresponding to the AS events represented on the mouse AS microarray indicated that 514 (42.7%) of the 1204 AS events located in genes with known ORFs have the potential to result in the introduction of a PTC and trigger NMD (Supplementary Table S1); 172 (14.3%) of the AS events introduce a PTC upon inclusion of the alternative exon (“PTC-upon inclusion” category), and 342 (28.4%) of the AS events introduce a PTC upon skipping of the alternative exon (“PTC-upon exclusion” category). The remaining 690 (57.3%) AS events are not expected to introduce a PTC or activate NMD (“No PTC” category). Global suppression of PTC-containing splice variants in mammalian tissues A comparison of the percent exon exclusion levels among the three AS event categories across the 10 mouse tissues revealed striking differences that are consistent with the widespread suppression of splice variants that contain PTCs introduced by AS: 84.9% of the AS events in the PTC-upon inclusion category have an average percent exon exclusion level >50% (i.e., overall high alternative exon exclusion), while, in contrast, 92.1% of the AS events in the PTC-upon exclusion category have an average percent exon exclusion level <50% (i.e., overall high alternative exon inclusion) (Fig. 1A We also analyzed steady-state transcript levels of the same genes that were analyzed for percent exon exclusion levels in the three AS event categories in Figure 1A The data in Figure 1A The results described above are consistent with previous proposals that NMD may act efficiently and on a frequent basis to reduce the levels of PTC-containing transcripts. However, it is also possible that many of the PTC-containing splice variants are initially produced at low levels, independently of the action of NMD. In order to investigate this possibility, we next analyzed the global effects of depletion of the critical NMD factor UPF1 on the percent exon exclusion levels of alternative exons that do or do not have the potential to introduce PTCs. Global analysis of the role of UPF1 in reducing PTC-containing splice variants Using a new microarray designed for the quantitative profiling of 3055 sequence-verified human cassette-type AS events (Fig. 2
Consistent with a critical role for NMD in the removal of PTC-containing transcripts, increased ratios of PTC-containing to non-PTC-containing splice variants were observed for 80%-90% of AS events that displayed a change in exon exclusion level in cells depleted of UPF1 (Fig. 2C At a significantly lower frequency (0%-10% of PTC-introducing AS events that display a 15% or greater change in exon exclusion level), depletion of UPF1 also resulted in increased ratios of predicted non-PTC-containing to PTC-containing splice variants (Fig. 2C We also examined the effects of UPF1 knockdown on transcript levels (using averages of the signals from flanking constitutive exon probes on the microarray), both for the subset of genes that display a significant change in percent exon exclusion level, and also for all genes corresponding to the top half-ranking GenASAP AS events analyzed in the PTC-upon inclusion/exclusion and No PTC categories in Figure 2A In order to investigate the effects of UPF1 depletion on transcript levels further, we performed RT-PCR assays on sets of AS events that display a range of UPF1-dependent changes in percent exon exclusion in the PTC-upon inclusion/exclusion and No PTC categories. Representative RT-PCR reactions from each AS event category are shown in Supplementary Figure S4. Interestingly, it is apparent from the RT-PCR data that depletion of UPF1, while generally resulting in increased levels of PTC-containing splice variants, in many cases also results in the simultaneous decrease in level of non-PTC-containing splice variants, such that the overall transcript levels are not significantly altered. In other cases analyzed, the change in splice variant ratio detected in the microarray data and by RT-PCR assay involved only very minor increases in PTC-containing variants, without detectable decreases in the non-PTC-containing splice variant from the same genes, but the resulting total transcript level changes may be below the limit of the sensitivity of detection on the microarray. These results therefore show that UPF1-dependent changes in percent exon exclusion levels on average do not detectably affect transcript levels of the corresponding genes. Moreover, consistent with the results of a recent microarray profiling study showing that the transcript levels for ~9% of human genes show at least a 1.9-fold increase or decrease upon depletion of UPF1 (Mendell et al. 2004), we find that the transcript levels for ~6% of the genes measured on the human AS microarray are affected to the same extent by depletion of UPF1 (data not shown). However, consistent with the results in Figure 2 The results described above provide evidence that NMD may only play a limited role in the suppression of PTC-containing splice variants. The majority of PTC-containing transcripts produced by AS do not appear to undergo pronounced UPF1-dependent suppression but instead are already present at low abundance. Thus, taken together with the results in Figure 1 Global selection pressure acting against PTC-introducing AS events To further assess the possible functional significance of the majority of PTC-containing splice variants, which, based on our microarray data, are generally found to be present at low abundance levels, we next determined what proportion of these are mouse-specific versus conserved between human and mouse (Fig. 3
Conclusions Ongoing analyses of human and mouse genome and transcript sequence data, as well as microarray studies, are documenting a vast repertoire of alternative spliced mRNAs. A major question of the post-genomic era, therefore, is the extent to which these alternatively spliced transcripts are functionally significant. Combined with information from sequence analyses on the conservation of these splice variants, as well as computational predictions as to which AS events have the potential to introduce PTCs that can activate NMD, our results address this question using an experimental, microarray-based approach that allows the levels of thousands of these splice variants to be simultaneously monitored in individual cell and tissue types. Importantly, our observation stemming from the use of this system indicating that the majority of PTC-containing transcripts are present at uniformly low abundance levels in normal mammalian tissues, and that only a relatively small proportion of PTC-containing splice variants appear to be substantially regulated by NMD, suggests that functionally important AS events are concentrated among the remaining two-thirds of AS events that do not introduce PTCs. Materials and methods Identification of AS events in human and mouse transcripts Detection and filtering of AS events were performed essentially as described previously (Pan et al. 2004, 2005). To identify cassette and mutually exclusive AS events in human transcripts, we used cDNA/EST sequences data from UniGene (ftp://ftp.ncbi.nih.gov/repository/UniGene; Build #158) and human genome sequence data (ftp://ftp.ncbi.nih.gov/genomes/H_sapiens). Cell culture, transfection, RNA purification, and protein analysis Human HeLa cells (2 × 108) were propagated in DMEM medium (GIBCO-BRL) containing 10% fetal bovine serum (GIBCO-BRL) and transiently transfected with 100 nM in vitro synthesized siRNA (Dharmacon) using Oligofectamine (Invitrogen). Protein and total RNA were isolated 3 d later. Control and UPF1 siRNAs and conditions for Western blotting were described previously (Kim et al. 2005). Additional information is provided in the Supplemental Material. Microarray hybridization, image processing, and data analysis Microarray design, hybridization, and data analysis for 3055 human AS events (represented on a single 22K Agilent microarray) were performed essentially as described previously (Pan et al. 2004). Information on AS events represented on the human microarray is provided in Supplementary Table S3. Analysis of percent exon exclusion levels for 3126 AS events in 10 mouse tissues was performed using data described in our previous study (Pan et al. 2004). The microarray analysis of AS levels in HeLa cells treated with siRNAs (Fig. 2 Detection of PTC-containing splice variants and categorization of conserved and species-specific alternative exons Available information on ORFs for genes represented in the human and mouse AS microarrays (Figs. (Figs.1,1 RT-PCR assays RT-PCR reactions (Supplementary Figs. S2, S4) were carried out as described previously (Pan et al. 2004, 2005), with modifications as described in the Supplemental Material. Acknowledgments We thank Leo Lee for help with data analysis; and John Calarco, Timothy Hughes, Jim Ingles, Joanna Ip, May Khanna, Susan McCracken, and Miles Wilkinson for helpful discussions and comments on the manuscript. We are also grateful to Jens Lykke-Andersen for the anti-UPF1 antibody. Y.K.K. and L.E.M. are supported by GM059614. O.S. and A.L.S. are sup-ported by NSERC graduate scholarships. This work was supported by operating grants from the CIHR and NCIC to B.J.B. Notes Supplemental material is available at http://www.genesdev.org and http://www.utoronto.ca/intron/AS. Article and publication are at http://www.genesdev.org/cgi/doi/10.1101/gad.1382806. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||
Trends Genet. 2001 Feb; 17(2):100-7.
[Trends Genet. 2001]Annu Rev Biochem. 2003; 72():291-336.
[Annu Rev Biochem. 2003]Trends Biochem Sci. 2000 Aug; 25(8):381-8.
[Trends Biochem Sci. 2000]Trends Genet. 2002 Apr; 18(4):186-93.
[Trends Genet. 2002]Nat Rev Genet. 2002 Apr; 3(4):285-98.
[Nat Rev Genet. 2002]Genome Biol. 2004; 5(2):R8.
[Genome Biol. 2004]Nat Rev Mol Cell Biol. 2004 Feb; 5(2):89-99.
[Nat Rev Mol Cell Biol. 2004]Bioessays. 2005 May; 27(5):463-6.
[Bioessays. 2005]Nat Genet. 2004 Oct; 36(10):1073-8.
[Nat Genet. 2004]Curr Biol. 2005 May 24; 15(10):963-7.
[Curr Biol. 2005]Bioinformatics. 2003; 19 Suppl 1():i118-21.
[Bioinformatics. 2003]Genome Biol. 2004; 5(2):R8.
[Genome Biol. 2004]Genome Biol. 2004; 5(4):218.
[Genome Biol. 2004]Bioessays. 2005 May; 27(5):463-6.
[Bioessays. 2005]Curr Opin Cell Biol. 2005 Jun; 17(3):309-15.
[Curr Opin Cell Biol. 2005]Mol Cell. 2004 Dec 22; 16(6):929-41.
[Mol Cell. 2004]Mol Cell. 2004 Dec 22; 16(6):929-41.
[Mol Cell. 2004]Mol Cell. 2004 Dec 22; 16(6):929-41.
[Mol Cell. 2004]J Biol. 2004; 3(5):21.
[J Biol. 2004]Cell. 2005 Jan 28; 120(2):195-208.
[Cell. 2005]Nat Genet. 2004 Oct; 36(10):1073-8.
[Nat Genet. 2004]Nat Genet. 2003 Jun; 34(2):177-80.
[Nat Genet. 2003]Trends Genet. 2005 Feb; 21(2):73-7.
[Trends Genet. 2005]Proc Natl Acad Sci U S A. 2005 Feb 22; 102(8):2850-5.
[Proc Natl Acad Sci U S A. 2005]RNA. 2004 Dec; 10(12):1838-44.
[RNA. 2004]Nucleic Acids Res. 2004; 32(4):1261-9.
[Nucleic Acids Res. 2004]Mol Cell. 2004 Dec 22; 16(6):929-41.
[Mol Cell. 2004]Trends Genet. 2005 Feb; 21(2):73-7.
[Trends Genet. 2005]Cell. 2005 Jan 28; 120(2):195-208.
[Cell. 2005]Mol Cell. 2004 Dec 22; 16(6):929-41.
[Mol Cell. 2004]Trends Biochem Sci. 1998 Jun; 23(6):198-9.
[Trends Biochem Sci. 1998]Mol Cell. 2004 Dec 22; 16(6):929-41.
[Mol Cell. 2004]Trends Genet. 2005 Feb; 21(2):73-7.
[Trends Genet. 2005]Cell. 2005 Jan 28; 120(2):195-208.
[Cell. 2005]Cell. 2000 Dec 22; 103(7):1121-31.
[Cell. 2000]Trends Genet. 2005 Feb; 21(2):73-7.
[Trends Genet. 2005]